Literature DB >> 2887574

The gene for ornithine decarboxylase is co-amplified in hydroxyurea-resistant hamster cells.

P R Srinivasan, P N Tonin, E J Wensing, W H Lewis.   

Abstract

We have constructed a cDNA library from the highly hydroxyurea-resistant hamster cell line 600H in which the activity of ribonucleotide reductase is elevated more than 80-fold. Using the technique of differential hybridization, we have isolated a number of cDNA clones from this library which are homologous to genomic DNA sequences amplified in the 600H cell line compared to the V79 parental line. One of these cDNA clones by sequence analysis was found to code for ornithine decarboxylase. This was confirmed by in vitro translation of poly(A+) RNA isolated by hybridization-selection followed by immunoprecipitation with antiserum specific for mouse ornithine decarboxylase. Genomic sequences homologous to the cDNA clone were shown to be sequentially amplified 6-20-fold in hamster cell lines selected stepwise for resistance to increasing concentrations of hydroxyurea. Genomic sequences homologous to a cDNA for the M2 subunit of ribonucleotide reductase were also amplified in these cell lines, and the degree of M2 sequence amplification corresponded to the degree of amplification of ornithine decarboxylase sequences, suggesting that the two genes had been co-amplified during the selection of the hydroxyurea-resistant phenotype.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2887574

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  The gene for a novel protein, a member of the protein disulphide isomerase/form I phosphoinositide-specific phospholipase C family, is amplified in hydroxyurea-resistant cells.

Authors:  M M Chaudhuri; P N Tonin; W H Lewis; P R Srinivasan
Journal:  Biochem J       Date:  1992-02-01       Impact factor: 3.857

2.  Nucleotide sequence of the Chinese hamster ornithine decarboxylase gene.

Authors:  A Grens; C Steglich; R Pilz; I E Scheffler
Journal:  Nucleic Acids Res       Date:  1989-12-25       Impact factor: 16.971

3.  Nucleotide sequence of the mouse ornithine decarboxylase gene.

Authors:  P Coffino; E L Chen
Journal:  Nucleic Acids Res       Date:  1988-03-25       Impact factor: 16.971

4.  Transcripts from amplified sequences of an inherited homogeneously staining region in chromosome 1 of the house mouse (Mus musculus).

Authors:  W A Eckert; C Plass; A Weith; W Traut; H Winking
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

5.  Regulation of mouse ornithine decarboxylase activity by cell growth, serum and tetradecanoyl phorbol acetate is governed primarily by sequences within the coding region of the gene.

Authors:  T van Daalen Wetters; M Brabant; P Coffino
Journal:  Nucleic Acids Res       Date:  1989-12-11       Impact factor: 16.971

6.  Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential.

Authors:  B S Zhou; P Tsai; R Ker; J Tsai; R Ho; J Yu; J Shih; Y Yen
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 4.510

7.  Identification and characterization of a gene that is coamplified with dihydrofolate reductase in a methotrexate-resistant CHO cell line.

Authors:  P K Foreman; J L Hamlin
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

8.  Domains within the mammalian ornithine decarboxylase messenger RNA have evolved independently and episodically.

Authors:  G J Johannes; F G Berger
Journal:  J Mol Evol       Date:  1993-06       Impact factor: 2.395

9.  Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.

Authors:  Ai-Guo Lu; Hao Feng; Pu-Xiong-Zhi Wang; Ding-Pei Han; Xue-Hua Chen; Min-Hua Zheng
Journal:  World J Gastroenterol       Date:  2012-09-14       Impact factor: 5.742

10.  Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.

Authors:  Stephen I Shibata; James H Doroshow; Paul Frankel; Timothy W Synold; Yun Yen; David R Gandara; Heinz-Josef Lenz; Warren A Chow; Lucille A Leong; Dean Lim; Kim A Margolin; Robert J Morgan; George Somlo; Edward M Newman
Journal:  Cancer Chemother Pharmacol       Date:  2009-03-26       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.